In situ breast carcinoma incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of in situ breast carcinoma, 2015-2017, UK.

 

Age

Peak rate of breast carcinoma in situ cases, 2015-2017, UK

 

Trend over time

Change in breast carcinoma in situ incidence rates since the early 1990s, UK

 

Breast carcinoma in situ incidence rates (European age-standardised (AS) rates Open a glossary item) for persons are significantly lower than the UK average in Scotland, and similar to the UK average in all other UK constituent countries.

Breast Carcinoma In Situ (D05), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 7,014 476 428 245 8,163
Crude Rate 24.9 17.1 27.0 25.8 24.4
AS Rate 25.9 16.6 26.2 27.6 25.1
AS Rate - 95% LCL 25.3 15.2 23.7 24.2 24.6
AS Rate - 95% UCL 26.5 18.1 28.6 31.1 25.7
Male Cases 35 2 3 1 41
Crude Rate 0.1 0.1 0.2 0.1 0.1
AS Rate 0.1 0.1 0.2 0.1 0.1
AS Rate - 95% LCL 0.1 0.0 0.0 0.0 0.1
AS Rate - 95% UCL 0.2 0.2 0.4 0.3 0.2
Persons Cases 7,049 478 431 246 8,204
Crude Rate 12.7 8.8 13.8 13.1 12.4
AS Rate 13.4 8.7 13.6 14.3 13.0
AS Rate - 95% LCL 13.1 7.9 12.3 12.5 12.7
AS Rate - 95% UCL 13.7 9.5 14.9 16.1 13.3

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item  around the AS Rate  Open a glossary item
 

For breast cancinoma in situ, like most cancer types, differences between countries largely reflect risk factor prevalence in years past.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 D05.

Last reviewed:

Breast carcinoma in situ incidence is related to age, with the highest incidence rates being in the 65 to 69 age group. In the UK in 2015-2017, on average each year around a tenth of new cases (9%) were in people aged 75 and over.[1-4] This is a lower proportion of cases in older age groups compared with most cancers.

Age-specific incidence rates in females, rise steeply from around age 35-39, then decrease steeply from age 65-69 and decrease steadily from age 75-79. In males rates increase from age 35-39.The highest rates are in in the 65 to 69 age group for females and the 85 to 89 age group for males.

Incidence rates are significantly higher in females than males in a number of (mainly older) age groups.The gap is widest at age 45 to 49, when the age-specific incidence rate is 900 times higher in females than males.

Breast carcinoma in situ (D05), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For breast carcinoma in situ, most cases are identified through the breast screening programme. Incidence peaks first when routine screening starts at age 50, with a brief drop shortly after which reflects the diagnosis of prevalent cases at first-time screening. Incidence then falls rapidly when routine screening ends at age 70.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, D05.

Last reviewed:

Breast carcinoma in situ European age-standardised (AS) Open a glossary item incidence rates for females and males combined increased by 194% in the UK between 1993-1995 and 2015-2017.[1-4] The increase was larger in females than in males.

For females, breast carcinoma in situ AS incidence rates in the UK increased by 195% between 1993-1995 and 2015-2017. For males, breast carcinoma in situ AS incidence rates in the UK increased by 93% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), breast carcinoma in situ AS incidence rates for females and males combined increased by 33%.[1-4] In females AS incidence rates increased by 33%, and in males rates remained stable.

Breast Carcinoma In Situ (ICD-10 D05), European Age-Standardised Incidence Rates, UK, 1993-2017

Breast carcinoma in situ incidence rates have increased overall in all broad age groups in females in the UK since the early 1990s.[1-4] Rates in 0-24s have increased by 632%, in 25-49s have increased by 183%, in 50-64s have increased by 118%, in 65-69s have increased by 612%, in 70-79s have increased by 463%, and in 80+s have increased by 441%.

Breast Carcinoma In Situ (ICD-10 D05), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2017

Breast carcinoma in situ incidence trends probably reflect the effective implementation of the UK breast screening programmes in the late 1980s, and subsequent extensions to the screening-eligible age group and improvements in screening methods – most cases are identified through the screening programme.[5] Changing prevalence of risk factors probably also plays a part.[5]

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  5. Glover JA, Bannon FJ, Hughes CM, et al. Increased diagnosis and detection rates of carcinoma in situ of the breast. Breast Cancer Res Treat. 2012;133(2):779-84 

About this data

Data is for UK, 1993-2017, ICD-10 D05.

Last reviewed:

Most in situ breast carcinoma cases are intraductal, and there is a much smaller proportion of lobular in situ breast carcinomas (2010-2012).[1-4]

A small proportion of cases did not have the specific part of the breast recorded in cancer registry data.[1-4]

Cases and percentages may not sum due to rounding

References

  1. Data were provided by the Office for National Statistics on request, July 2014. Similar data can be found here: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html.
  2. Data were provided by ISD Scotland on request, April 2014. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request, April 2014. Similar data can be found here: http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=59080.
  4. Data were provided by the Northern Ireland Cancer Registry on request, June 2014. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/CancerInformation/.

About this data

Data is for UK, 2010-2012, ICD-10 D05.

Last reviewed:

A quarter of women diagnosed with in situ breast carcinoma in England during 2006-2007 live in the least deprived areas of England, while only 13% live in the most deprived areas.[1] A similar distribution of cases by deprivation is also reported for invasive breast cancer.[1]

References

  1. West Midlands Cancer Intelligence Unit. The Non-Invasive Breast Cancer report: An analysis of non-invasive breast cancers diagnosed in England from 1 January 2006 to 31 December 2007. National Cancer Intelligence Unit, 2011. 

About this data:

Data is for UK, 2002-2006 and 2007-2011, ICD-10 D05

Deprivation gradient statistics were calculated using mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

The proportion of incidence cases in White females with in situ breast carcinoma is significantly higher than for Asian or Black females.[1]

A similar ethnic profile is also reported for invasive breast cancer.[2]

Analysis included unknown data. For in situ breast carcinoma, 5,460 cases were identified; 28% had no known ethnicity.

References

  1. West Midlands Cancer Intelligence Unit. The Non-Invasive Breast Cancer report: An analysis of non-invasive breast cancers diagnosed in England from 1 January 2006 to 31 December 2007 (PDF 342KB). National Cancer Intelligence Unit, 2011. 
  2. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.

About this data

Data is for England, 2006-2007, ICD-O2 & ICD-O3

Last reviewed:

An estimated 63,800 women who had been diagnosed with in situ breast carcinoma between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 D05

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.